cagrilintide vs semaglutide A new drug combo of (GLP-1 receptor agonist) with (amylin analogue) failed to do as well as tirzepatide (GLP-1/GIP receptor agonist). The future of these medicines is hitting different receptors Efficacy and safety of once-weekly
Description
Key markers include fasting glucose, HbA1c, insulin levels, triglycerides, and inflammatory markers like hsCRP
Common sites for this type of injection include the abdomen (around the belly button area) and thighs (front or outer parts)
How an endocrinologist actually decides In clinic, the decision between an oral GLP-1 pill and an injectable GLP-1 is built around the patient, not the medication
Regular Exercise: Aim for at least 150 minutes of moderate-intensity exercise weekly
Signal Transduct Target Ther 2024;9
